Association of vitamin D status with disease severity and outcome in Indian patients with IgA nephropathy.
25 (OH) vitamin D
IgA nephropathy
Outcome
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
17 01 2023
17 01 2023
Historique:
received:
30
04
2022
accepted:
11
01
2023
entrez:
17
1
2023
pubmed:
18
1
2023
medline:
20
1
2023
Statut:
epublish
Résumé
Vitamin D deficiency has been examined as a risk factor for severity and progression of kidney disease due to its immunomodulatory effects. There is paucity of data about its impact in IgA nephropathy (IgAN). In a retrospective cohort study, 25 (OH) vitamin D assay was performed in bio-banked baseline serum samples collected during kidney biopsy of 105 adult patients with primary IgAN diagnosed between 2015 and 2019. A level of < 10 ng/mL was defined as Vitamin D deficiency. Mean age of patients was 34 ± 10.6 years, 69.5% were males. Mean baseline 25(OH) Vitamin D levels was 15.9 ± 11.9 ng/mL and 41(39%) patients had vitamin D deficiency. Serum albumin level was lower in vitamin D deficient patients compared to those who had higher vitamin D levels (3.7 ± 0.9 vs 4.1 ± 0.7 g/dl, p = 0.018)but there was no significant difference in baseline proteinuria and eGFR. Crescentic lesions were more frequent in vitamin D deficient group (19.5% vs 6.3%, p = 0.022). At median follow up of 21.5 months (6 - 56 months), there was no difference in remission (68.3% vs 65.6%, p = 0.777) and disease progression (12.5% vs 9.4%, p = 0.614) in those with and without Vitamin D deficiency respectively. On multivariate cox proportional hazard analysis, vitamin D deficiency was not a significant risk factor for renal survival (HR-1.79, 95% confidence interval:0.50-6.34, p = 0.368). There was no association between vitamin D deficiency and disease profile as well as renal outcome in Indian patients with IgAN.
Sections du résumé
BACKGROUND
Vitamin D deficiency has been examined as a risk factor for severity and progression of kidney disease due to its immunomodulatory effects. There is paucity of data about its impact in IgA nephropathy (IgAN).
METHODS
In a retrospective cohort study, 25 (OH) vitamin D assay was performed in bio-banked baseline serum samples collected during kidney biopsy of 105 adult patients with primary IgAN diagnosed between 2015 and 2019. A level of < 10 ng/mL was defined as Vitamin D deficiency.
RESULTS
Mean age of patients was 34 ± 10.6 years, 69.5% were males. Mean baseline 25(OH) Vitamin D levels was 15.9 ± 11.9 ng/mL and 41(39%) patients had vitamin D deficiency. Serum albumin level was lower in vitamin D deficient patients compared to those who had higher vitamin D levels (3.7 ± 0.9 vs 4.1 ± 0.7 g/dl, p = 0.018)but there was no significant difference in baseline proteinuria and eGFR. Crescentic lesions were more frequent in vitamin D deficient group (19.5% vs 6.3%, p = 0.022). At median follow up of 21.5 months (6 - 56 months), there was no difference in remission (68.3% vs 65.6%, p = 0.777) and disease progression (12.5% vs 9.4%, p = 0.614) in those with and without Vitamin D deficiency respectively. On multivariate cox proportional hazard analysis, vitamin D deficiency was not a significant risk factor for renal survival (HR-1.79, 95% confidence interval:0.50-6.34, p = 0.368).
CONCLUSION
There was no association between vitamin D deficiency and disease profile as well as renal outcome in Indian patients with IgAN.
Identifiants
pubmed: 36650464
doi: 10.1186/s12882-023-03061-0
pii: 10.1186/s12882-023-03061-0
pmc: PMC9843909
doi:
Substances chimiques
Vitamin D
1406-16-2
Vitamins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15Informations de copyright
© 2023. The Author(s).
Références
BMC Nephrol. 2013 Oct 02;14:206
pubmed: 24083392
Int Urol Nephrol. 2020 Jan;52(1):129-136
pubmed: 31768803
Med Sci Monit. 2017 Jun 29;23:3170-3177
pubmed: 28659572
Mayo Clin Proc. 2010 Aug;85(8):752-7; quiz 757-8
pubmed: 20675513
Semin Nephrol. 2004 May;24(3):179-96
pubmed: 15156525
Kidney Int. 2009 Nov;76(9):977-83
pubmed: 19657329
Eur J Pharmacol. 2019 Feb 15;845:91-98
pubmed: 30287151
Postgrad Med J. 2012 Jan;88(1035):15-20
pubmed: 22052882
Kidney Int. 2017 May;91(5):1014-1021
pubmed: 28341274
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
Kidney Int. 2021 Oct;100(4S):S1-S276
pubmed: 34556256
Nephrology (Carlton). 2005 Oct;10(5):496-503
pubmed: 16221102
Am J Kidney Dis. 2008 May;51(5):724-31
pubmed: 18436082
BMC Nephrol. 2016 Nov 2;17(1):164
pubmed: 27806690
Clin J Am Soc Nephrol. 2009 Sep;4(9):1523-8
pubmed: 19478099
Kidney Int. 2010 Jun;77(11):1000-9
pubmed: 20182412
Kidney Int. 2009 Jan;75(1):88-95
pubmed: 18843258
Nutrients. 2014 Feb 21;6(2):729-75
pubmed: 24566435
J Biol Chem. 1995 Oct 13;270(41):23906-9
pubmed: 7592579
Nephrol Dial Transplant. 2011 Feb;26(2):414-30
pubmed: 21068142
Int J Vitam Nutr Res. 2015;85(3-4):185-201
pubmed: 26575971
Clin Nephrol. 2017 Jan;87 (2017)(1):21-27
pubmed: 27900938
Ren Fail. 2016;38(3):431-6
pubmed: 26837482
J Am Soc Nephrol. 2007 Jun;18(6):1796-806
pubmed: 17513326
Am J Kidney Dis. 2012 Jan;59(1):67-74
pubmed: 22019331
Curr Med Chem. 2018;25(27):3256-3271
pubmed: 29446731